Form 8-K - Current report:
SEC Accession No. 0001193125-24-169191
Filing Date
2024-06-26
Accepted
2024-06-26 17:14:56
Documents
19
Period of Report
2024-06-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d857341d8k.htm   iXBRL 8-K 36824
2 EX-1.1 d857341dex11.htm EX-1.1 206956
3 EX-4.1 d857341dex41.htm EX-4.1 85638
4 EX-5.1 d857341dex51.htm EX-5.1 14036
5 EX-99.1 d857341dex991.htm EX-99.1 9238
9 GRAPHIC g857341img01.jpg GRAPHIC 11011
10 GRAPHIC g857341img02.jpg GRAPHIC 19266
  Complete submission text file 0001193125-24-169191.txt   614236

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tsha-20240626.xsd EX-101.SCH 2845
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20240626_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20240626_pre.xml EX-101.PRE 11704
22 EXTRACTED XBRL INSTANCE DOCUMENT d857341d8k_htm.xml XML 3767
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 241074510
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)